Treatment Schedules for Presumptive Parasitic Infections
This table describes presumptive anti-parasitic treatment currently provided to the largest groups of U.S.-bound refugees. The first three columns list the region, departure country, and ethnicity/national origin of the refugees. The fourth column lists recommended presumptive treatment for parasites (including malaria).
|Region||Country of Processing||Principal Refugee Groups||Presumptive Parasite Treatment for Eligible Refugeesb||Special Notes|
|Africa||Chad||Central African Republic; Sudanese Darfuri||Albendazol Praziquantel Artemether-lumefantrine||Ivermectin is not administered to refugees who have resided or traveled in Loa loa-endemic countries due to risk of encephalopathy associated with ivermectin treatment in a person with Loa loa infection. See list of Loa loa-endemic countries.c|
|Burundi, Djibouti, Ethiopia, Kenya, Rwanda, South Africa, Tanzania, Uganda, others||Somali; Congolese; Ethiopian; Eritrean; Sudanese (other than Sudanese Darfuri); South Sudanese||Albendazole
|Of note, refugees of Congolese or South Sudanese origin who resided or traveled in Democratic Republic of Congo (DRC) or South Sudan do NOT receive ivermectin. However, children of Congolese or South Sudanese origin who were born in the camps in non Loa loa-endemic countries and have not resided or traveled in DRC or South Sudan are (usually) treated with ivermectin.
Only refugees from sub-Saharan Africa receive artemether-lumefantrine.
|Asia||Malaysia, Nepal, Pakistan, Thailand||Burma/Myanmar origin
(Karen, Karenni, Kachin, Rohingya);
|Indonesia, Sri Lanka||Multiple||Albendazole|
|Europe||Austria, Malta, Moldova, Russia, Ukraine||Multiple||None|
El Salvador, Guatemala, Honduras
|Cuban; Colombian; Salvadoran; Guatemalan; Honduran||None|
a Information provided by the International Organization for Migration (IOM) during required overseas refugee medical exam.
b Presumptive parasite treatments: albendazole (for soil-transmitted helminths), 400 mg for refugees > 2 years old, 200 mg for children 12-23 months of age; ivermectin (for Strongyloides), 200 μg/kg once a day for 2 days for adults and children weighing > 15kg; and praziquantel (for schistosomiasis), 40 mg/kg divided in 2 doses for adults and children > 4 yo.
Arthemether-lumifantrine (AL, for malaria) 6-dose treatment for adults and children weighing > 5kg.
c Ivermectin is not administered to refugees who resided or traveled in countries where Loa loa is endemic due to the risk of encephalopathy associated with ivermectin treatment in persons who are also infected with Loa loa. Countries that are currently considered endemic for Loa loa are Angola, Cameroon, Central African Republic, Chad, Democratic Republic of the Congo, Equatorial Guinea, Gabon, Nigeria, Republic of the Congo, and South Sudan.